Stockreport

Apellis Reports Analysis from Phase 1b Geographic Atrophy Study

Apellis Pharmaceuticals, Inc.  (APLS) 
PDF No cases of inflammation observed after 12 months with Phase 3 formulation of pegcetacoplan in patients with advanced geographic atrophy (GA)Decrease in mean lesion grow [Read more]